As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...

With the peak flu season often occurring during December and January and even into February, Dr. Sharon Nachman, Chief of the ...

French multinational pharmaceutical company Sanofi has commenced the shipping of BEYFORTUS (nirsevimab-alip) to the US, ...

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the ...

RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

Company planning for every eligible baby in the US to have access to BEYFORTUS <li /> New BEYFORTUS filling line approved by the ...

October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

Barclays analyst Emily Field maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €120.00. The ...